ATI RN
ATI Pharmacology Proctored Exam 2023
1. A client has a new prescription for Losartan. Which of the following laboratory values should the nurse monitor?
- A. Serum potassium
- B. Serum sodium
- C. Serum calcium
- D. Serum magnesium
Correct answer: A
Rationale: Corrected Rationale: Losartan, an angiotensin II receptor blocker (ARB), can cause hyperkalemia by affecting the renin-angiotensin-aldosterone system. Monitoring serum potassium levels is crucial to detect and manage any potential hyperkalemia, which can lead to serious cardiac arrhythmias. Monitoring serum sodium, calcium, or magnesium levels is not typically required when a patient is on Losartan unless there are specific indications or comorbidities that warrant such monitoring.
2. A client is starting therapy with bicalutamide. Which of the following adverse effects should the nurse instruct the client to monitor?
- A. Muscle pain
- B. Flushing
- C. Gynecomastia
- D. Hyperglycemia
Correct answer: C
Rationale: The correct answer is gynecomastia (Choice C). Bicalutamide is associated with gynecomastia due to its antiandrogenic properties. Gynecomastia, the development of breast tissue in males, is an important adverse effect to monitor when taking bicalutamide. Choices A, B, and D are incorrect. Muscle pain and flushing are not commonly associated with bicalutamide use. Hyperglycemia is not a typical adverse effect of bicalutamide therapy.
3. A client has been prescribed diltiazem (Cardizem) and asks the nurse what type of drug this is. Which response by the nurse is most appropriate?
- A. “A beta blocker.â€
- B. “A sodium channel blocker.â€
- C. “An alpha blocker.â€
- D. “A calcium channel blocker.â€
Correct answer: D
Rationale: Diltiazem (Cardizem) belongs to the class of drugs known as calcium channel blockers. These medications work by blocking calcium from entering the muscle cells of the heart and blood vessels, leading to relaxation of the blood vessels and reduced workload on the heart. This helps in lowering blood pressure and improving blood flow. It is crucial for the nurse to provide accurate information to the client about the type of drug prescribed to ensure understanding and compliance with the treatment plan.
4. A client is prescribed Diltiazem. Which of the following findings should the nurse monitor?
- A. Tachycardia
- B. Bradycardia
- C. Hypertension
- D. Hyperkalemia
Correct answer: B
Rationale: Diltiazem is a calcium channel blocker that can cause bradycardia as an adverse effect due to its negative chronotropic properties, slowing down the heart rate. Therefore, the nurse should monitor the client for signs of bradycardia by regularly assessing the heart rate to prevent potential complications. Monitoring for tachycardia (choice A) is incorrect as diltiazem typically does not cause tachycardia. Hypertension (choice C) is not a typical finding to monitor for with diltiazem use. Hyperkalemia (choice D) is not directly associated with diltiazem administration.
5. A healthcare professional is caring for a client who has a new prescription for Lisinopril. Which of the following laboratory values should the professional monitor?
- A. Serum potassium
- B. Serum sodium
- C. Serum calcium
- D. Serum magnesium
Correct answer: A
Rationale: Lisinopril is an ACE inhibitor that can cause hyperkalemia by reducing the excretion of potassium in the kidneys. Monitoring serum potassium levels is essential to prevent complications such as cardiac arrhythmias. Therefore, the healthcare professional should closely monitor the client's serum potassium levels when they are on Lisinopril. Choices B, C, and D are incorrect because Lisinopril primarily affects potassium levels due to its mechanism of action as an ACE inhibitor. Serum sodium, calcium, and magnesium levels are not typically affected by Lisinopril in the same way as potassium.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access